AbbVie (ABBV) Tops Q4 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance

AbbVie (NYSE: ABBV) reported Q4 EPS of $2.71, $0.06 better than the analyst estimate of $2.65. Revenue for the quarter came in at $16.62 billion versus the consensus estimate of $16.39 billion.

GUIDANCE:

AbbVie sees FY2026 EPS of $14.37-$14.57, versus the consensus of $14.22.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings